Vera Therapeutics, Inc. (VERA) Stock Analysis
Healthcare · Biotechnology · NasdaqGM
Vera Therapeutics, Inc. (VERA) posted $0 in revenue for fiscal 2025, with a net loss of $299.62M, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Vera Therapeutics, Inc.
Vera Therapeutics, Inc. has grown revenue from $0 to $0 over the last 6 fiscal years.
It carries about $74.84M of total debt.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Vera Therapeutics, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Vera Therapeutics, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — |
| Net income | $-53.41M | $-32.61M | $-89.06M | $-95.99M | $-152.15M | $-299.62M |
| Net margin | — | — | — | — | — | — |
Source: Vera Therapeutics, Inc. SEC filings (10-K).
Vera Therapeutics, Inc.: 2 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 156.3% over 3 years (27.8M → 71.3M) — existing holders' stakes are being diluted.
- Debt with negative operating cash flowCarries $74.8M of debt while last year's operating cash flow was negative ($-241.1M).
Explore 6 years of Vera Therapeutics, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track VERA in your portfolio →
Vera Therapeutics, Inc. financial history by metric
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
Vera Therapeutics, Inc. — frequently asked questions
What is Vera Therapeutics, Inc.'s revenue?
Vera Therapeutics, Inc. (VERA) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Vera Therapeutics, Inc. profitable?
No — VERA reported a net loss of $-299.62M in fiscal 2025.
What is VERA's P/E ratio?
Vera Therapeutics, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Vera Therapeutics, Inc. have?
As of fiscal year 2025, VERA carried roughly $74.84M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Vera Therapeutics, Inc.'s market cap?
Vera Therapeutics, Inc. (VERA) has a market capitalization of about $2.39B, based on the latest data in our nightly-refreshed cache.
When does Vera Therapeutics, Inc.'s fiscal year end?
VERA's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Vera Therapeutics, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.